<p>Founders Capital Management LLC 在最近向证券交易委员会提交的文件中表示，在第二季度将其在再生元制药公司（NASDAQ:REGN - 免费报告）的持股增加了 7.0%。这家机构投资者在该季度额外购买了 538 股后，持有该生物制药公司 8,274 股股票。再生元制药占 Founders Capital Management LLC 投资组合的 0.7%，是其第 25 大持股。到最近一个季度末，Founders Capital Management LLC 在再生元制药的持股价值为 4,344,000 美元。</p>
<ul>
<li>大熊：3 只接近一年低点的股票，可能在 2025 年大幅上涨</li>
</ul>
<p>其他一些对冲基金和机构投资者也调整了对 REGN 的持股。GAMMA Investing LLC 在第一季度将其在再生元制药的持股增加了 89,825.0%。GAMMA Investing LLC 目前持有 815,620 股该生物制药公司的股票，价值 517,291,000 美元，此前在上个季度额外购买了 814,713 股。Nuveen LLC 在第一季度购买了再生元制药的新头寸，价值 343,764,000 美元。Pacer Advisors Inc.在第一季度将其在再生元制药的持股增加了 2,296.9%。Pacer Advisors Inc.目前持有 407,370 股该生物制药公司的股票，价值 258,366,000 美元，此前在上个季度额外购买了 390,374 股。Assenagon Asset Management S.A.在第一季度将其在再生元制药的持股增加了 171.0%。Assenagon Asset Management S.A.目前持有 481,389 股该生物制药公司的股票，价值 305,311,000 美元，此前在上个季度额外购买了 303,785 股。最后，Universal Beteiligungs und Servicegesellschaft mbH 在第四季度购买了再生元制药的新头寸，价值 127,215,000 美元。目前 83.31% 的股票由机构投资者和对冲基金持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>REGN 最近受到了一些分析师报告的关注。富国银行将再生元制药的评级从 “增持” 下调至 “持平”，并为该公司设定了 580.00 美元的目标价。在 8 月 1 日星期五的报告中，Truist Financial 将再生元制药的目标价从 940.00 美元下调至 812.00 美元，并在 8 月 11 日星期一的报告中为该公司设定了 “买入” 评级。花旗集团在 8 月 1 日星期五的研究报告中重申了 “买入” 评级，并为再生元制药的股票发布了 650.00 美元的目标价。杰富瑞金融集团在 8 月 27 日星期三的研究报告中将再生元制药的目标价从 813.00 美元上调至 831.00 美元，并给予该公司 “买入” 评级。最后，Argus 在 6 月 30 日星期一的研究报告中将再生元制药的评级从 “买入” 下调至 “持有”。三位研究分析师对该股票给予了强烈买入评级，十八位给予了买入评级，六位给予了持有评级，一位给予了卖出评级。根据 MarketBeat，该公司目前的共识评级为 “适度买入”，共识目标价为 817.67 美元。</p>
<ul>
<li>2025 年最佳生物科技股票</li>
</ul>
<p><strong>查看我们关于再生元制药的最新研究报告</strong></p>
<h2>再生元制药股票表现</h2>
<p>再生元制药的股票在周一开盘价为 591.99 美元。该股票的 50 日移动平均价格为 567.77 美元，200 日移动平均价格为 574.26 美元。该公司的市值为 627.5 亿美元，市盈率为 14.92，市盈增长比率为 1.98，贝塔值为 0.35。该公司的债务与股本比率为 0.09，速动比率为 3.72，流动比率为 4.60。再生元制药的股票在过去一年中的最低价为 476.49 美元，最高价为 1,154.56 美元。</p>
<ul>
<li>3 只拥有坚实资产负债表的股票，适合长期稳定投资</li>
</ul>
<p>再生元制药（NASDAQ:REGN - 获取免费报告）最近在 8 月 1 日星期五发布了季度财报。这家生物制药公司报告的季度每股收益为 12.89 美元，超出市场共识预期的 8.43 美元，超出幅度为 4.46 美元。该公司季度收入为 36.8 亿美元，而分析师预期为 33 亿美元。再生元制药的股本回报率为 15.06%，净利润率为 31.37%。再生元制药的季度收入同比增长 3.6%。在去年同期，该公司每股收益为 11.56 美元。整体来看，卖方分析师预计再生元制药将在当前财政年度发布 35.92 美元的每股收益。</p>
<h2>再生元制药宣布分红</h2>
<p>该公司最近还宣布了季度分红，已于 9 月 3 日星期三支付。8 月 18 日星期一的登记投资者获得了每股 0.88 美元的分红。该分红的除息日期为 8 月 18 日星期一。这代表着每年 3.52 美元的分红，收益率为 0.6%。再生元制药的派息比率为 8.87%。</p>
<h2>再生元制药简介</h2>
<p>（免费报告）</p>
<p>再生元制药公司在全球范围内发现、发明、开发、生产和商业化治疗各种疾病的药物。该公司的产品包括用于治疗湿性年龄相关性黄斑变性和糖尿病性黄斑水肿的 EYLEA 注射剂；近视性脉络膜新生血管；糖尿病视网膜病；新生血管性青光眼；以及早产儿视网膜病。</p>
<h2>另见</h2>
<ul>
<li>我们更看好的五只股票，胜过再生元制药</li>
<li>2022-2025 年股市假期 - 纽约证券交易所和纳斯达克的休市时间</li>
<li>GameStop 像 2021 年一样狂欢：2025 年反弹背后的原因是什么？</li>
<li>金融服务股票投资</li>
<li>3 只被忽视的价值股，预计在利率下降时大幅上涨</li>
<li>最活跃的股票：美元交易量与股数交易量</li>
<li>Hims &amp; Hers 股票因医疗保健降息狂潮而推高至新高</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在再生元制药吗？</h2>
<p>在你考虑再生元制药之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而再生元制药并不在名单上。</p>
<p>虽然再生元制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

再生元制药

<p>Founders Capital Management LLC 在第二季度将其在再生元制药（Regeneron Pharmaceuticals, Inc.，NASDAQ:REGN）的持股增加了 7.0%，目前持有 8,274 股，价值 434 万美元。其他机构投资者也显著增加了他们的持仓。分析师对 REGN 的评级意见不一，普遍评级为 “适度买入”，目标价为 817.67 美元。再生元公布了强劲的第二季度财报，每股收益（EPS）为 12.89 美元，超出预期。公司宣布每股派发季度股息 0.88 美元，将于 9 月 3 日支付</p>

<p>Founders Capital Management LLC grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 7.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,274 shares of the biopharmaceutical company's stock after purchasing an additional 538 shares during the quarter. Regeneron Pharmaceuticals makes up 0.7% of Founders Capital Management LLC's investment portfolio, making the stock its 25th largest position. Founders Capital Management LLC's holdings in Regeneron Pharmaceuticals were worth $4,344,000 at the end of the most recent quarter.</p>
<div class="lb-trans"><p>Founders Capital Management LLC 在最近向证券交易委员会提交的文件中表示，在第二季度将其在再生元制药公司（NASDAQ:REGN - 免费报告）的持股增加了 7.0%。这家机构投资者在该季度额外购买了 538 股后，持有该生物制药公司 8,274 股股票。再生元制药占 Founders Capital Management LLC 投资组合的 0.7%，是其第 25 大持股。到最近一个季度末，Founders Capital Management LLC 在再生元制药的持股价值为 4,344,000 美元。</p>
</div><ul>
<li>Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>大熊：3 只接近一年低点的股票，可能在 2025 年大幅上涨</li>
</ul>
</div><p>A number of other hedge funds and other institutional investors have also modified their holdings of REGN. GAMMA Investing LLC raised its holdings in shares of Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock valued at $517,291,000 after purchasing an additional 814,713 shares in the last quarter. Nuveen LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 1st quarter valued at $343,764,000. Pacer Advisors Inc. grew its position in Regeneron Pharmaceuticals by 2,296.9% during the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock worth $258,366,000 after purchasing an additional 390,374 shares during the last quarter. Assenagon Asset Management S.A. grew its position in Regeneron Pharmaceuticals by 171.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock worth $305,311,000 after purchasing an additional 303,785 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Regeneron Pharmaceuticals during the 4th quarter worth $127,215,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他一些对冲基金和机构投资者也调整了对 REGN 的持股。GAMMA Investing LLC 在第一季度将其在再生元制药的持股增加了 89,825.0%。GAMMA Investing LLC 目前持有 815,620 股该生物制药公司的股票，价值 517,291,000 美元，此前在上个季度额外购买了 814,713 股。Nuveen LLC 在第一季度购买了再生元制药的新头寸，价值 343,764,000 美元。Pacer Advisors Inc.在第一季度将其在再生元制药的持股增加了 2,296.9%。Pacer Advisors Inc.目前持有 407,370 股该生物制药公司的股票，价值 258,366,000 美元，此前在上个季度额外购买了 390,374 股。Assenagon Asset Management S.A.在第一季度将其在再生元制药的持股增加了 171.0%。Assenagon Asset Management S.A.目前持有 481,389 股该生物制药公司的股票，价值 305,311,000 美元，此前在上个季度额外购买了 303,785 股。最后，Universal Beteiligungs und Servicegesellschaft mbH 在第四季度购买了再生元制药的新头寸，价值 127,215,000 美元。目前 83.31% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>REGN has been the subject of a number of recent analyst reports. Wells Fargo &amp; Company downgraded Regeneron Pharmaceuticals from an &#34;overweight&#34; rating to an &#34;equal weight&#34; rating and set a $580.00 target price for the company. in a report on Friday, August 1st. Truist Financial reduced their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a &#34;buy&#34; rating for the company in a report on Monday, August 11th. Citigroup restated a &#34;buy&#34; rating and issued a $650.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, August 1st. Jefferies Financial Group raised their price target on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the company a &#34;buy&#34; rating in a research report on Wednesday, August 27th. Finally, Argus cut Regeneron Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research report on Monday, June 30th. Three research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $817.67.</p>
<div class="lb-trans"><p>REGN 最近受到了一些分析师报告的关注。富国银行将再生元制药的评级从 “增持” 下调至 “持平”，并为该公司设定了 580.00 美元的目标价。在 8 月 1 日星期五的报告中，Truist Financial 将再生元制药的目标价从 940.00 美元下调至 812.00 美元，并在 8 月 11 日星期一的报告中为该公司设定了 “买入” 评级。花旗集团在 8 月 1 日星期五的研究报告中重申了 “买入” 评级，并为再生元制药的股票发布了 650.00 美元的目标价。杰富瑞金融集团在 8 月 27 日星期三的研究报告中将再生元制药的目标价从 813.00 美元上调至 831.00 美元，并给予该公司 “买入” 评级。最后，Argus 在 6 月 30 日星期一的研究报告中将再生元制药的评级从 “买入” 下调至 “持有”。三位研究分析师对该股票给予了强烈买入评级，十八位给予了买入评级，六位给予了持有评级，一位给予了卖出评级。根据 MarketBeat，该公司目前的共识评级为 “适度买入”，共识目标价为 817.67 美元。</p>
</div><ul>
<li>Best Biotech Stocks to Buy in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2025 年最佳生物科技股票</li>
</ul>
</div><p><strong>Check Out Our Latest Research Report on Regeneron Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们关于再生元制药的最新研究报告</strong></p>
</div><h2>Regeneron Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>再生元制药股票表现</h2>
</div><p>Regeneron Pharmaceuticals stock opened at $591.99 on Monday. The stock's 50 day moving average price is $567.77 and its 200 day moving average price is $574.26. The firm has a market capitalization of $62.75 billion, a PE ratio of 14.92, a price-to-earnings-growth ratio of 1.98 and a beta of 0.35. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.60. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,154.56.</p>
<div class="lb-trans"><p>再生元制药的股票在周一开盘价为 591.99 美元。该股票的 50 日移动平均价格为 567.77 美元，200 日移动平均价格为 574.26 美元。该公司的市值为 627.5 亿美元，市盈率为 14.92，市盈增长比率为 1.98，贝塔值为 0.35。该公司的债务与股本比率为 0.09，速动比率为 3.72，流动比率为 4.60。再生元制药的股票在过去一年中的最低价为 476.49 美元，最高价为 1,154.56 美元。</p>
</div><ul>
<li>3 Stocks With Ironclad Balance Sheets for Long-Term Stability</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只拥有坚实资产负债表的股票，适合长期稳定投资</li>
</ul>
</div><p>Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 EPS for the quarter, topping the consensus estimate of $8.43 by $4.46. The firm had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.Regeneron Pharmaceuticals's revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the previous year, the company posted $11.56 EPS. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>再生元制药（NASDAQ:REGN - 获取免费报告）最近在 8 月 1 日星期五发布了季度财报。这家生物制药公司报告的季度每股收益为 12.89 美元，超出市场共识预期的 8.43 美元，超出幅度为 4.46 美元。该公司季度收入为 36.8 亿美元，而分析师预期为 33 亿美元。再生元制药的股本回报率为 15.06%，净利润率为 31.37%。再生元制药的季度收入同比增长 3.6%。在去年同期，该公司每股收益为 11.56 美元。整体来看，卖方分析师预计再生元制药将在当前财政年度发布 35.92 美元的每股收益。</p>
</div><h2>Regeneron Pharmaceuticals Announces Dividend</h2>
<div class="lb-trans"><h2>再生元制药宣布分红</h2>
</div><p>The business also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is 8.87%.</p>
<div class="lb-trans"><p>该公司最近还宣布了季度分红，已于 9 月 3 日星期三支付。8 月 18 日星期一的登记投资者获得了每股 0.88 美元的分红。该分红的除息日期为 8 月 18 日星期一。这代表着每年 3.52 美元的分红，收益率为 0.6%。再生元制药的派息比率为 8.87%。</p>
</div><h2>Regeneron Pharmaceuticals Profile</h2>
<div class="lb-trans"><h2>再生元制药简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.</p>
<div class="lb-trans"><p>再生元制药公司在全球范围内发现、发明、开发、生产和商业化治疗各种疾病的药物。该公司的产品包括用于治疗湿性年龄相关性黄斑变性和糖尿病性黄斑水肿的 EYLEA 注射剂；近视性脉络膜新生血管；糖尿病视网膜病；新生血管性青光眼；以及早产儿视网膜病。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Regeneron Pharmaceuticals</li>
<li>Stock Market Holidays 2022-2025 - Here’s When the NYSE and NASDAQ Will be Closed</li>
<li>GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound?</li>
<li>Financial Services Stocks Investing</li>
<li>3 Overlooked Value Stocks Set to Surge as Rates Drop</li>
<li>Most active stocks: Dollar volume vs share volume</li>
<li>Hims &amp; Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，胜过再生元制药</li>
<li>2022-2025 年股市假期 - 纽约证券交易所和纳斯达克的休市时间</li>
<li>GameStop 像 2021 年一样狂欢：2025 年反弹背后的原因是什么？</li>
<li>金融服务股票投资</li>
<li>3 只被忽视的价值股，预计在利率下降时大幅上涨</li>
<li>最活跃的股票：美元交易量与股数交易量</li>
<li>Hims &amp; Hers 股票因医疗保健降息狂潮而推高至新高</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkVHTg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=REGN"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在再生元制药吗？</h2>
</div><p>Before you consider Regeneron Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑再生元制药之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前... 而再生元制药并不在名单上。</p>
</div><p>While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然再生元制药目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Founders Capital Management LLC 购买了再生元制药公司 $REGN 的股份